Invest
EU policy reforms and pharma investments highlight shifting industry priorities
Invest
EU policy reforms and pharma investments highlight shifting industry priorities
In a significant move to bolster the pharmaceutical landscape across Europe, the European Parliament's rapporteur has unveiled draft reforms to the proposed EU Critical Medicines Act. These reforms aim to enhance investment in domestic manufacturing and expand stockpiling measures, ensuring a steady supply of medicines across EU member states. The draft legislation broadens the definition of "medicines of common interest" and extends investment incentives beyond just critical medicines. It also introduces multi-winner procurement, minimum supply commitments, and an EU coordination mechanism to manage shortages. This initiative signals a shift in industry priorities, according to GlobalData, a leading data and analytics company.
EU policy reforms and pharma investments highlight shifting industry priorities
In a significant move to bolster the pharmaceutical landscape across Europe, the European Parliament's rapporteur has unveiled draft reforms to the proposed EU Critical Medicines Act. These reforms aim to enhance investment in domestic manufacturing and expand stockpiling measures, ensuring a steady supply of medicines across EU member states. The draft legislation broadens the definition of "medicines of common interest" and extends investment incentives beyond just critical medicines. It also introduces multi-winner procurement, minimum supply commitments, and an EU coordination mechanism to manage shortages. This initiative signals a shift in industry priorities, according to GlobalData, a leading data and analytics company.
Eóin Ryan, Manager of Health Economics and Market Access at GlobalData, commented on the implications of these proposals: “The proposals strengthen investment channels for both common and critical medicines and reinforce Europe’s manufacturing base. However, expanding stockpiling obligations could increase administrative and cost burdens for companies already facing tight margins.”
The discussions surrounding these reforms are set to continue into 2026, as the EU seeks to strike a balance between strategic autonomy and market efficiency. The emphasis on domestic manufacturing and stockpiling is seen as a response to recent global supply chain disruptions and the need for Europe to ensure its pharmaceutical independence.
In parallel with these policy developments, significant investments in the pharmaceutical sector are unfolding on the other side of the Atlantic. GlobalData’s Bio/Pharmaceutical Outsourcing Report highlights GSK's announcement of a massive $30 billion, five-year investment to expand its R&D and manufacturing capabilities in the United States. This investment includes $1.2 billion earmarked for advanced technologies and the construction of a new biologics flex factory in Upper Merion, Pennsylvania, slated to begin in 2026.
GSK CEO Emma Walmsley has emphasised the company's continued commitment to its UK roots, stating that GSK will keep investing over $2.3 billion annually in research and development. This dual investment strategy underscores GSK’s approach to balancing its global presence. Janet Beal, Managing Analyst for Health Economics and Market Access at GlobalData, noted: “GSK’s dual investment strategy demonstrates a clear commitment to strengthening its US footprint while maintaining confidence in its UK base. This approach reflects a broader industry trend to balance global competitiveness amid shifting policy and trade dynamics.”
The landscape of pharmaceutical investment is further enriched by FUJIFILM Biotechnologies USA's announcement of a $2 billion investment, funded by Johnson & Johnson. This investment will be used to construct a 160,000-square-foot facility at its Holly Springs site, creating approximately 120 new jobs and expanding US capacity for advanced medicines. Meanwhile, Capitol Biologics is set to offer comprehensive early-phase biologics development and GMP manufacturing services for private biotech firms and US government agencies. These services will adhere to a unified quality system aligned with FDA, EMA, and ICH standards.
The Bio/Pharmaceutical Outsourcing Report, a monthly analysis of trends affecting pharmaceutical contract manufacturing organisations (CMOs), provides insights into the latest contract manufacturing agreements, opportunities, and threats for CMOs, as well as mergers and acquisitions and emerging regulatory news.
These developments highlight a broader trend within the pharmaceutical industry, where companies are navigating a complex web of policy changes and investment opportunities to secure their positions in an increasingly competitive global market. As the EU works towards greater strategic autonomy, and companies like GSK and FUJIFILM Biotechnologies USA expand their investment portfolios, the industry is poised for transformative changes that could redefine the future of pharmaceutical manufacturing and supply.
RELATED ARTICLES
Investment insights
RBA keeps the playbook open: how to navigate an “anything-can-happen” rate path
The Reserve Bank has kept its options open on interest rates, signalling neither cuts nor hikes are off the table. For boards and CFOs, that ambiguity is not a bug — it’s the game. With the cash rate ...Read more
Investment insights
Hotter CPI, cooler cuts: What the RBA pause means for balance sheets, pricing and 2025 strategy
A surprise upside in quarterly inflation has shifted the Reserve Bank of Australia’s calculus: a cut now looks less likely, and a prolonged plateau in rates more probable. For CFOs, that changes the ...Read more
Investment insights
Gold demand hits record highs as investors seek refuge from market volatility
Global gold demand surged to record levels in the September quarter as investors sought safety amid volatile markets and growing geopolitical uncertainty, according to the World Gold Council’s Q3 2025 ...Read more
Investment insights
Global deal activity dips 4% amid cautious investor sentiment: GlobalData
Global deal activity has declined by 4 per cent year-on-year during the first three quarters of 2025 as deal-making slowed across regions and sectors, according to data and analytics firm GlobalDataRead more
Investment insights
RBA easing risk returns: How a possible November cut reshapes capital, currency and competitiveness
A four-year high in unemployment has put the Reserve Bank of Australia back in play, with major sell-side houses flagging a live risk of a November rate cut. For CFOs and boards, this is more than a ...Read more
Investment insights
Master the market with a cool head: Building durable portfolios in a heated economy
With investor activity in Australia back at an eight‑year high, the most expensive mistakes aren’t about picking the ‘wrong’ asset — they’re about running an undisciplined processRead more
Investment insights
State Street warns of potential rate cuts as unemployment rises
In a development that has captured the attention of financial analysts and policymakers alike, the latest Labour Force data released today reveals a significant shift in Australia's employment ...Read more
Investment insights
Gold’s new playbook: from safe haven to strategic reserve as prices hit records
Gold’s rally to record territory in 2025 is not a speculative sideshow—it is a structural signal. With central banks accelerating diversification away from US Treasuries, real yields easing, and ...Read more
Investment insights
RBA keeps the playbook open: how to navigate an “anything-can-happen” rate path
The Reserve Bank has kept its options open on interest rates, signalling neither cuts nor hikes are off the table. For boards and CFOs, that ambiguity is not a bug — it’s the game. With the cash rate ...Read more
Investment insights
Hotter CPI, cooler cuts: What the RBA pause means for balance sheets, pricing and 2025 strategy
A surprise upside in quarterly inflation has shifted the Reserve Bank of Australia’s calculus: a cut now looks less likely, and a prolonged plateau in rates more probable. For CFOs, that changes the ...Read more
Investment insights
Gold demand hits record highs as investors seek refuge from market volatility
Global gold demand surged to record levels in the September quarter as investors sought safety amid volatile markets and growing geopolitical uncertainty, according to the World Gold Council’s Q3 2025 ...Read more
Investment insights
Global deal activity dips 4% amid cautious investor sentiment: GlobalData
Global deal activity has declined by 4 per cent year-on-year during the first three quarters of 2025 as deal-making slowed across regions and sectors, according to data and analytics firm GlobalDataRead more
Investment insights
RBA easing risk returns: How a possible November cut reshapes capital, currency and competitiveness
A four-year high in unemployment has put the Reserve Bank of Australia back in play, with major sell-side houses flagging a live risk of a November rate cut. For CFOs and boards, this is more than a ...Read more
Investment insights
Master the market with a cool head: Building durable portfolios in a heated economy
With investor activity in Australia back at an eight‑year high, the most expensive mistakes aren’t about picking the ‘wrong’ asset — they’re about running an undisciplined processRead more
Investment insights
State Street warns of potential rate cuts as unemployment rises
In a development that has captured the attention of financial analysts and policymakers alike, the latest Labour Force data released today reveals a significant shift in Australia's employment ...Read more
Investment insights
Gold’s new playbook: from safe haven to strategic reserve as prices hit records
Gold’s rally to record territory in 2025 is not a speculative sideshow—it is a structural signal. With central banks accelerating diversification away from US Treasuries, real yields easing, and ...Read more
